• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: W. L. GORE & ASSOCIATES, INC. GORE-TEX® STRETCH VASCULAR GRAFT; PROSTHESIS, VASCULAR GRAFT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

W. L. GORE & ASSOCIATES, INC. GORE-TEX® STRETCH VASCULAR GRAFT; PROSTHESIS, VASCULAR GRAFT Back to Search Results
Catalog Number S0604
Device Problem Contamination (1120)
Patient Problem Unspecified Infection (1930)
Event Date 09/01/2016
Event Type  Injury  
Event Description
Gore received an adverse event alert from a retrospective vascular graft study.On (b)(6) 2016, the patient underwent surgical treatment for the creation of a vascular access graft brachio-basilic in the left arm for hemodialysis with a gore-tex® stretch vascular graft, because of an access site infection of a jugular catheter.The device was implanted and retained and there were no adverse events during the procedure.The patient was discharged home on (b)(6) 2016, and the first order to dialyze through the graft successfully was on (b)(6) 2016.On (b)(6) 2016, the patient presented with an infection of the prosthetic loop graft.Medical or surgical intervention was needed, and treatment required.The issue was resolved on (b)(6) 2016.The study was discontinued, as the device was explanted.
 
Manufacturer Narrative
A1: no patient specific details have been provided.Therefore, the patient initials reflect the study number with codes for the hospital and patient.H3 other code: as it is unknown, if the device is available, no further investigation can be performed.H6 evaluation codes investigation findings c19 refers to the product history review: a review of the manufacturing records indicated the lots met all pre-release specifications.The physician was contacted and further details requested.Further investigation is being conducted and will be included in the final report.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
 
Manufacturer Narrative
This mwr report was submitted by human error and therefore this report is being retracted.Reason for vascular graft implantation was access site infection of a cvc.No systemic infection was reported, instead local infection was reported.No information was provided as to whether this local infection affected the brachio-basilic av bypass graft during or after implantation.When comparing access sites for cvc and brachio-basilic av bypass graft, it is reasonable to assume that local cvc access site infection does not affect a brachio-basilic av bypass graft implantation.It was reported that the av bypass graft was repeatedly cannulated for hemodialysis as of (b)(6), 2016.(b)(6) 2016, was given as the onset date of the brachio-basilic av bypass graft infection.The event description, no further information was provided, the anatomical locations of access sites and the chronological sequence reasonably suggest a connection between graft cannulation and infection.Gore´s internal worldwide reporting guideline states that for event categories"infection, graft", a graft which was previously cannulated for av access is considered not reportable.
 
Manufacturer Narrative
As the status of the device is unknown, no further investigation of the device can be performed.Neither clinical images enabling direct assessment of product performance, nor the device was returned for evaluation.Multiple attempts were made to obtain additional information about this event from the physician, like how was the infection diagnosed, was this a systemic bacterial infection, are bacteriology findings available that confirm the infection, was the explanted gore device replaced by another device, was there a pre-existing infection in the field of treatment and/or was there an infection at the access site? no further details were provided.With the information provided to gore, the cause of the reported event cannot be established.In the instruction for use for the gore-tex® stretch vascular graft the following is stated: possible complications with the use of any vascular prosthesis complications which may occur in conjunction with the use of any vascular prosthesis include but are not limited to: infection.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GORE-TEX® STRETCH VASCULAR GRAFT
Type of Device
PROSTHESIS, VASCULAR GRAFT
Manufacturer (Section D)
W. L. GORE & ASSOCIATES, INC.
1505 n. fourth street
flagstaff AZ 86004
Manufacturer (Section G)
MEDICAL WEST B/P
1505 n. fourth street
flagstaff AZ 86004
Manufacturer Contact
gunter marte
1505 n. fourth street
flagstaff, AZ 86004
9285263030
MDR Report Key17676110
MDR Text Key322621629
Report Number2017233-2023-04249
Device Sequence Number1
Product Code DSY
UDI-Device Identifier00733132611294
UDI-Public00733132611294
Combination Product (y/n)N
Reporter Country CodeFR
PMA/PMN Number
K903931
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Study,Health Professional,User Facility
Reporter Occupation Physician
Type of Report Initial,Followup,Followup
Report Date 12/06/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received09/04/2023
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date02/17/2021
Device Catalogue NumberS0604
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received12/05/2023
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured02/19/2016
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age78 YR
Patient SexMale
-
-